BI Asset Management Fondsmaeglerselskab A S Takes Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

BI Asset Management Fondsmaeglerselskab A S bought a new position in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 272,634 shares of the company's stock, valued at approximately $6,009,000.

Other institutional investors have also made changes to their positions in the company. Stifel Financial Corp lifted its position in Teva Pharmaceutical Industries by 54.0% in the 3rd quarter. Stifel Financial Corp now owns 66,391 shares of the company's stock valued at $1,196,000 after purchasing an additional 23,283 shares during the last quarter. Robeco Institutional Asset Management B.V. raised its holdings in shares of Teva Pharmaceutical Industries by 7.2% during the fourth quarter. Robeco Institutional Asset Management B.V. now owns 498,309 shares of the company's stock valued at $10,983,000 after buying an additional 33,277 shares during the last quarter. Pinnbrook Capital Management LP acquired a new position in shares of Teva Pharmaceutical Industries during the fourth quarter worth approximately $4,966,000. Asset Management One Co. Ltd. grew its holdings in Teva Pharmaceutical Industries by 14.6% in the 4th quarter. Asset Management One Co. Ltd. now owns 457,371 shares of the company's stock worth $10,414,000 after buying an additional 58,413 shares in the last quarter. Finally, CWA Asset Management Group LLC acquired a new stake in Teva Pharmaceutical Industries in the 4th quarter valued at approximately $3,340,000. 54.05% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the stock. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research note on Wednesday. Bank of America dropped their price target on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating on the stock in a research report on Thursday, March 6th. Barclays lowered their price objective on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a research note on Thursday, January 30th. UBS Group cut their target price on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a research report on Thursday, January 30th. Finally, Piper Sandler lifted their price target on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an "overweight" rating in a research report on Friday, January 17th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $23.43.

Teva Pharmaceutical Industries Trading Up 1.1 %

TEVA traded up $0.16 during trading on Friday, reaching $14.88. The company had a trading volume of 6,566,648 shares, compared to its average volume of 9,930,429. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98. Teva Pharmaceutical Industries Limited has a 12-month low of $12.47 and a 12-month high of $22.80. The company has a market cap of $16.87 billion, a price-to-earnings ratio of -10.26, a PEG ratio of 1.44 and a beta of 0.72. The firm's 50-day simple moving average is $15.23 and its 200 day simple moving average is $17.56.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. Equities research analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.